000			01943cam a2200361 a 4500
001			421361492
003			OCoLC
005			20150408114107.0
008			090701s2010 nyua b 001 0 eng
010			_a2009027407
015			_aGBB011488 _2bnb
020			_a9780195367294 (alk. paper)
020			_a0195367294 (alk. paper)
040			_aDNLM/DLC _cDLC _dYDX _dNLM _dYDXCP _dUKM
042			_apcc
050	0	0	_aRM315 _b.M73 2010
050	0	0	_aRM315 _b.M73 2010
060	1	0	_aQV 38 _bM939p 2010
082	0	0	_a615.788 _222 _bMDP
100	1		_aMrazek, David. _919067
245	1	0	_aPsychiatric pharmacogenomics / _cDavid A. Mrazek.
260			_aNew York : _bOxford University Press, _c2010.
300			_ax, 265 p. : _bill. (some col.) ; _c25 cm.
504			_aIncludes bibliographical references and index.
505	0		_aThe language of molecular genetics -- The fourteen genes -- The problem and the solution -- The cytochrome P450 2D6 gene -- The cytochrome P450 2C19 gene -- The cytochrome P450 2C9 gene -- The cytochrome P450 1A2 gene -- The catechol-o-methyltransferase gene -- The norepinephrine transporter gene -- The dopamine transporter gene -- The serotonin transporter gene -- The serotonin 1A receptor gene -- The serotonin 2A receptor gene -- The serotonin 2C receptor gene -- The dopamine D2 receptor gene -- The dopamine D3 receptor gene -- The dopamine D4 receptor gene -- The clinical utility of psychiatric pharmacogenomic testing -- Ethical issues to consider when using pharmacogenomic testing in psychiatric practice -- The future development of psychiatric pharmacogenomic testing.
650		0	_aPsychotropic drugs. _919068
650		0	_aPharmacogenomics. _919069
650	1	2	_aBiotransformation _xgenetics. _919070
650	1	2	_aPsychotropic Drugs _xadverse effects. _919071
650	2	2	_aMental Disorders _xdrug therapy. _919072
650	2	2	_aPsychotropic Drugs _xpharmacokinetics. _919073
942			_2ddc _cDVD
999			_c26655 _d261155